PBDC1

Across TCGA pan-cancer cohorts, PBDC1 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of PBDC1’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where PBDC1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types PBDC1 is over-expressed in tumor, although a few such as HNSC show the opposite, repressed pattern.

CCRCC, LUAD, and COAD are the cancer types where PBDC1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PBDC1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	II,III,IV	+0.173	<.001	10	view →
LUAD	Female	II,III,IV	+0.393	<.001	9	view →
COAD	Female	All	+0.227	<.001	9	view →
LSCC	Male	All	+0.152	<.001	6	view →
PDAC	All	All	+0.193	.002	4	view →
HNSC	All	IV	−0.141	.028	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

PBDC1–CCRCC

Open the CCRCC breakdown →